GXO’s first quarter results were supported by notable revenue growth and exceeded Wall Street expectations, prompting a positive market response. Management attributed the quarter’s performance to strong new business wins, especially in the healthcare sector, and a faster-than-expected ramp-up of new facilities. CEO Malcolm Wilson highlighted the landmark contract with the U.K. National Health Services supply chain as the company’s largest ever, crediting it to the successful integration of the Clipper Logistics acquisition. In addition to new contract momentum, operational productivity initiatives and continued investment in automation drove improved site-level efficiency across GXO’s regional footprint, while existing customer relationships deepened, notably with Boeing and Siemens Healthineers.
Is now the time to buy GXO? Find out in our full research report (it’s free).
GXO Logistics (GXO) Q1 CY2025 Highlights:
- Revenue: $2.98 billion vs analyst estimates of $2.94 billion (21.2% year-on-year growth, 1.4% beat)
- Adjusted EPS: $0.29 vs analyst estimates of $0.25 (14.5% beat)
- Adjusted EBITDA: $163 million vs analyst estimates of $154.8 million (5.5% margin, 5.3% beat)
- Revenue Guidance for Q2 CY2025 is $2.97 billion at the midpoint, below analyst estimates of $3.05 billion
- Management reiterated its full-year Adjusted EPS guidance of $2.50 at the midpoint
- EBITDA guidance for the full year is $850 million at the midpoint, above analyst estimates of $843.1 million
- Operating Margin: -1.9%, in line with the same quarter last year
- Organic Revenue rose 2.7% year on year (1% in the same quarter last year)
- Market Capitalization: $5.75 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions GXO Logistics’s Q1 Earnings Call
- Joe Hafling (Jefferies) asked about scenario planning behind maintaining guidance in a dynamic macro environment. CFO Baris Oran responded that flat volumes are the base assumption and downside scenarios are built in, citing a “narrow guidance range.”
- Brian Ossenbeck (JPMorgan) inquired about the ramp and cost implications of the NHS contract and broader healthcare opportunities. CEO Malcolm Wilson explained that startup costs are expected to be minimal due to the takeover-in-place model, emphasizing long-term pipeline growth from this vertical.
- Ravi Shanker (Morgan Stanley) probed the risk of contract renewal cliffs as pandemic-era deals reach maturity. Wilson clarified that contract renewals are staggered and customer relationships are typically renewed before expiration, with no sign of unusual churn.
- Chris Wetherbee (Wells Fargo) questioned the impact of tariffs on new business pipeline conversations. Wilson noted no material slowdown, stating that most pipeline opportunities are long-term and the recent sales organization redesign has improved win rates.
- Ben Moore (Citi) sought clarity on the shape of direct operating expenses post-Wincanton and share buyback strategy. Oran explained higher OpEx was driven by Wincanton’s business mix and noted share repurchases will be balanced against other capital priorities moving forward.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will monitor (1) the pace and financial impact of Wincanton’s integration and associated cost synergies, (2) the scaling of AI and automation initiatives and their contribution to operational efficiency, and (3) continued momentum in healthcare and other targeted verticals. Updates on customer pipeline conversion and any macro-driven shifts in demand will also serve as important indicators of ongoing execution.
GXO Logistics currently trades at $50.24, up from $38.11 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
